Hematology

What we do

Established in 1990, our department serves as a primary tertiary center for hematologic care across the Boso Peninsula, Chiba Prefecture, Tokyo, and nationwide. Operating 78 dedicated inpatient beds (including 16 specialized sterile cleanrooms), we are one of Japan’s largest and most advanced centers for blood disorders.

As a certified specialist training facility for the Japanese Society of Hematology, the Japan Marrow Donor Program (JMDP), and the Japan Cord Blood Bank Network, we provide cutting-edge diagnostic and therapeutic care for leukemia, lymphoma, multiple myeloma, and bone marrow failure syndromes.

Key Departmental Strengths & Clinical Highlights

High-Volume Hematopoietic Stem Cell Transplantation (HSCT):

Over 400 allogeneic transplants (bone marrow, cord blood, and peripheral blood stem cells) and over 200 autologous transplants performed to date.
Pioneering Care for Elderly Patients: Exceptional clinical outcomes in autologous and allogeneic transplants for patients aged 60 to 70+ with multiple myeloma, leukemia, or aggressive lymphoma.

National Leadership in Minimal Residual Disease (MRD): Utilizing 8-to-10-color Flow Cytometry for routine, highly sensitive detection of MRD in multiple myeloma and hematologic malignancies.

Rapid Diagnostic Protocols: Integrated workflows with clinical pathology enabling lymph node biopsy surface marker analysis and H&E histology within 3 days, alongside monthly joint case reviews with leading hematopathologists.

Advanced Laboratory & Transfusion Support: Equipped with cell-processing clean benches, blood irradiators, component separators, ultra-low temperature freezers (-135C), and rapid drug monitoring for immunocompromised and GVHD care (e.g., Tacrolimus, Cyclosporine, Aspergillus antigen).

Prolific Global Research Output: Active clinical trial generation and publication in top international journals (Blood, Blood Advances, Haematologica, British Journal of Haematology, Cancer, Mayo Clinic Proceedings).

Global Academic Contributions & Notable Publications

Our department actively presents at major domestic and international symposia, including the American Society of Hematology (ASH), European Hematology Association (EHA), and ASTCT.

Selected High-Impact Publications:

Random Skin Biopsy for Intravascular Lymphoma: Mayo Clin Proc. 2007, Br J Dermatol. 2019, Blood 2019, BJH 2019.

Hepatitis B Reactivation in Transplant/Rituximab Patients: Cancer 2010.

Multiple Myeloma & Renal/Immunological Markers: Blood Cancer J. 2014, Haematologica 2019.

Predictive Imaging (MDCT) in MDS & Myeloma: Leukemia 2018, Blood Advances 2018.

COVID-19 Vaccine Antibody Responses in Hematologic Patients: BJH 2021, BJH 2022, HemaSphere 2023.

Conditions we handle

We deliver comprehensive inpatient and outpatient diagnostic, targeted, and transplant therapies for a full spectrum of adult blood disorders:

Acute & Chronic Leukemias: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL).

Malignant Lymphomas: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (including intravascular large B-cell lymphoma and neurolymphomatosis).

Plasma Cell Dyscrasias: Multiple Myeloma, Smoldering Myeloma, Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS).

Bone Marrow Failure & Myelodysplastic Syndromes: Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH - detected via high-sensitivity assays).

Myeloproliferative Neoplasms (MPN): Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis.

Number of cases

In hematology / oncology department, medical treatment is mainly focused on hematopoietic malignancies such as leukemia, lymphoma, myeloma, and MDS. Recently, about 60 to 70 inpatients have been treated in our department. In addition, evidence-based treatment is also performed for patients with blood diseases other than malignant tumors such as aplastic anemia, autoimmune hemolytic anemia, ITP, TTP, and other hemorrhagic diseases.

Hematopoietic stem cell transplantation already started in our department 20 years ago, and the total number of allogeneic stem cell transplantation has reached 160 cases to date. In addition to unrelated bone marrow transplants via bone marrow banks, many cord blood transplants are also performed. Especially, the average age of patients undergoing hematopoietic stem cell transplantation is high in the latter half of their 50s, but the results are good. Treatments using hematopoietic stem cell transplantation have been used for various diseases in recent years due to the introduction of mini-transplantation, etc. We are actively engaged in this, and we believe that it can be expected for solid cancer and severe autoimmune diseases in the future.

List of Doctors

Chief of Hematology

Kosei MATSUE

Subspeciality
Hematology and Oncology

Department name	Hematology
Medical School	Kagoshima University Medical School
Special Qualifications	Board Certified Physician and Advanced Certified Specialist of Japanese Society of Internal Medicine Board Certified Physician and Advanced Specialist of Japanese Society of Hematology Board Advanced Certified Specialist of Japanese Society of Medical Oncology
Education & Career	1975.Mar. Graduated from Kagoshima University Medical School 1975.Apr. Resident of Kanazawa University Hospital 1976.May. Kanazawa Medical University 1976.Oct. Kagoshima University Hospital 1977.Apr. Kanazawa University Hospital 1980.Jun. National Kanazawa Wakamatsu Hospital 1982.May. Toyama Prefecture Saiseikai Takaoka Hospital 1982.Dec. Ishikawa Prefecture Nanao City Keijyu Hospital 1983.Apr. Assistant Professor， Kanazawa University Hospital 1983.Apr. Lecturer， Kanazawa University Hospital 1984.Sep. Fred Hutchinson Cancer Research Center 1987.May. Vice Chief and Lecuturer of Hamatology Kanazawa University Hospital 1989.Jun.

Associate Chief

Masami TAKEUCHI

Subspeciality
Hematology and Oncology

Department name	Hematology
Medical School	Saga Medical School Faculty of Medicine， Saga University
Special Qualifications	Japanese Society of Internal Medicine Japanese Society of Hematology Japan Society of Clinical Hematology
Education & Career	1992: Graduated from Saga Medical School Faculty of Medicine， Saga University 1992: Residency， Kameda Medical Center 1996: Hematology-Oncology， Kameda Medical Center 1998: Assistant Chief of Hematology-Oncology， Kameda Medical Center 2007: Vice Chief of Blood Transfusion Department， Kameda Medical Center

Andrology